Reliance Life Sciences (RLS), part of India's largest conglomerate, is expected to start phase I clinical studies of its indigenous Covid-19 vaccine soon. The Subject Expert Committee (SEC), which advises the drug regulator on vaccines and new drugs, reviewed the company’s application and is learnt to have recommended it for approval on Thursday. A formal nod to conduct trials of the two-dose jab is expected over the next few days.

Reliance Life Sciences (RLS), part of India's largest conglomerate, is expected to start phase I clinical studies of its indigenous Covid-19 vaccine soon. The Subject Expert Committee (SEC), which advises the drug regulator on vaccines and new drugs, reviewed the company’s application and is learnt to have recommended it for approval on Thursday. A formal nod to conduct trials of the two-dose jab is expected over the next few days.